BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

Advanced Search

11 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.EBI
Sanofi Us
Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.EBI
Sanofi Us
Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.EBI
Sanofi Us
Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).EBI
Sanofi Us
Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).EBI
Sanofi Us
Design and synthesis of D1 agonist/D2 antagonist for treatment of schizophrenia.EBI
Sanofi Us
An integrated computational workflow for efficient and quantitative modeling of renin inhibitors.EBI
Sanofi Us
X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase.EBI
Sanofi Us
Decreasing the CYP2D6 contribution to metabolism of a CK1ε inhibitor.EBI
Sanofi Us
Amelioration of PXR-mediated CYP3A4 induction by mGluR2 modulators.EBI
Sanofi Us
Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor.EBI
Sanofi Us